E
CYT

Ergoteles’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Ergoteles’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,148
Closed -$49.7K – 1900
2022
Q4 		$49.7K Buy
+30,148
New +$48.4K ﹤0.01% 1292
2022
Q3 		– Sell
-10,278
Closed -$31K – 2119
2022
Q2 		$31K Buy
+10,278
New +$26.2K ﹤0.01% 1574
2022
Q1 		– Sell
-13,355
Closed -$152K – 1719
2021
Q4 		$152K Buy
+13,355
New +$204K 0.01% 1093

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Ergoteles's CYT Position: Q1 2023 in Review

Ergoteles sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2023, closing a stake of 30,148 shares — an estimated $49.7K sold.

Ergoteles first reported a position in CYT in Q4 2021 and held it in 3 quarters. The position peaked at $152K in Q4 2021. 32 funds tracked by Wall St. Rank hold CYT as of Q1 2023.

  • Ergoteles reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 30,148 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $49.7K.
  • Ergoteles first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Ergoteles's Cyteir Therapeutics, Inc. Common Stock position peaked at $152K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.